Back to top

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review ...

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer | ENGN Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

enGene Holdings Inc. (ENGN)